2019
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal Of Medicine 2019, 381: 603-613. PMID: 31180194, PMCID: PMC6776880, DOI: 10.1056/nejmoa1902226.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, Monoclonal, HumanizedCD3 ComplexChildDiabetes Mellitus, Type 1Disease ProgressionDouble-Blind MethodExanthemaFemaleGlucose Tolerance TestHLA-DR3 AntigenHLA-DR4 AntigenHumansLymphocyte CountLymphopeniaMaleMiddle AgedProportional Hazards ModelsT-LymphocytesYoung AdultConceptsType 1 diabetesClinical type 1 diabetesTeplizumab groupPlacebo groupOral glucose tolerance testInsulin-producing beta cellsDouble-blind trialChronic autoimmune diseaseGlucose tolerance testRelatives of patientsRate of diagnosisHigh-risk participantsTransient lymphopeniaAdverse eventsHazard ratioHLA-DR3HLA-DR4Median timeClinical progressionAutoimmune diseasesExogenous insulinCD3 antibodyT cellsTeplizumabClinical diseaseNoninvasive diagnosis of recurrent autoimmune type 1 diabetes after islet cell transplantation
Korutla L, Rickels MR, Hu RW, Freas A, Reddy S, Habertheuer A, Harmon J, Korutla V, Ram C, Naji A, Vallabhajosyula P. Noninvasive diagnosis of recurrent autoimmune type 1 diabetes after islet cell transplantation. American Journal Of Transplantation 2019, 19: 1852-1858. PMID: 30801971, PMCID: PMC7043773, DOI: 10.1111/ajt.15322.Peer-Reviewed Original ResearchConceptsIslet cell transplantationAutoimmune type 1 diabetesType 1 diabetesCell transplantationT1D autoimmunityNoninvasive diagnosisPancreatic β-cell injuryGlutamic acid decarboxylase 65Time-matched analysisΒ-cell injuryTransplanted β-cellsHyperglycemia onsetIslet injuryRecurrent autoimmunityHypoglycemic unawarenessTime-specific increaseIslet autoantigensCurative therapyT1D patientsImmunologic rejectionExogenous insulinInjury typeControl subjectsIslet transplantationDonor islets
2012
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2012, 56: 391-400. PMID: 23086558, PMCID: PMC3537871, DOI: 10.1007/s00125-012-2753-4.Peer-Reviewed Original ResearchConceptsC-peptide responseType 1 diabetesImmune therapyHigh C-peptide responseCentral randomisation centreChronic autoimmune processPlacebo-treated participantsPlacebo-controlled trialPrimary outcome analysisC-peptide levelsCharacteristics of patientsSubgroup of patientsC-peptide productionTeplizumab groupClinical respondersAutoimmune processPrimary outcomeExogenous insulinMixed mealSubgroup analysisResultsThirty-fourInsulin secretionTreatment benefitBaseline imbalancesTeplizumab
1991
SUPPRESSION OF COUNTERREGULATORY HORMONE RESPONSE TO HYPOGLYCEMIA BY INSULIN PER SE
DIAMOND M, HALLARMAN L, STARICK-ZYCH K, JONES T, CONNOLLY-HOWARD M, TAMBORLANE W, SHERWIN R. SUPPRESSION OF COUNTERREGULATORY HORMONE RESPONSE TO HYPOGLYCEMIA BY INSULIN PER SE. The Journal Of Clinical Endocrinology & Metabolism 1991, 72: 1388-1390. PMID: 2026760, DOI: 10.1210/jcem-72-6-1388.Peer-Reviewed Original ResearchConceptsCounterregulatory hormone responsesHormone responseGlucose levelsNormal subjectsCounterregulatory hormone levelsResponses of epinephrineVariable glucose infusionDegree of hyperinsulinemiaHigh-dose studiesHypoglycemic clamp studiesHypoglycemic counterregulationHypoglycemic stimulusInsulin doseExogenous insulinDose studyHormone levelsGlucose infusionClamp studiesHypoglycemiaGrowth hormoneHypoglycemic plateauInsulinModulating effectOnly variableHyperinsulinemia
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply